See more : Vtech Holdings Limited (VTKLY) Income Statement Analysis – Financial Results
Complete financial analysis of Vapotherm, Inc. (VAPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vapotherm, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Covivio Hotels (COVH.PA) Income Statement Analysis – Financial Results
- MCX Technologies Corporation (MCX.V) Income Statement Analysis – Financial Results
- Charoong Thai Wire and Cable Public Company Limited (CTW.BK) Income Statement Analysis – Financial Results
- Celadon Pharmaceuticals Plc (CEL.L) Income Statement Analysis – Financial Results
- Cartesian Growth Corporation (GLBLW) Income Statement Analysis – Financial Results
Vapotherm, Inc. (VAPO)
About Vapotherm, Inc.
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 68.67M | 66.80M | 113.29M | 125.73M | 48.10M | 42.38M | 35.60M | 30.12M |
| Cost of Revenue | 40.39M | 49.56M | 60.10M | 62.69M | 26.79M | 25.61M | 22.36M | 20.18M |
| Gross Profit | 28.28M | 17.24M | 53.19M | 63.05M | 21.31M | 16.77M | 13.24M | 9.94M |
| Gross Profit Ratio | 41.19% | 25.81% | 46.95% | 50.14% | 44.30% | 39.58% | 37.19% | 33.00% |
| Research & Development | 14.21M | 20.80M | 18.41M | 16.96M | 13.38M | 8.77M | 7.57M | 6.21M |
| General & Administrative | 19.26M | 27.80M | 31.38M | 24.04M | 18.41M | 11.19M | 8.02M | 5.94M |
| Selling & Marketing | 32.55M | 46.09M | 60.14M | 65.07M | 37.69M | 33.93M | 26.22M | 20.03M |
| SG&A | 51.81M | 73.89M | 91.52M | 89.10M | 56.10M | 45.11M | 34.24M | 25.97M |
| Other Expenses | 0.00 | 0.00 | 18.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.03M | 94.69M | 109.93M | 106.06M | 69.48M | 53.88M | 41.81M | 32.18M |
| Cost & Expenses | 106.41M | 144.25M | 170.03M | 168.75M | 96.27M | 79.49M | 64.17M | 52.36M |
| Interest Income | 78.00K | 139.00K | 91.00K | 257.00K | 860.00K | 118.00K | 3.00K | 8.00K |
| Interest Expense | 18.73M | 11.64M | 2.60M | 4.71M | 5.10M | 3.06M | 2.23M | 716.00K |
| Depreciation & Amortization | 4.98M | 5.18M | 5.65M | 4.77M | 3.08M | 2.17M | 1.53M | 1.34M |
| EBITDA | -34.36M | -100.39M | -52.40M | -43.01M | -44.89M | -37.23M | -27.24M | -20.89M |
| EBITDA Ratio | -47.60% | -107.97% | -45.00% | -30.21% | -91.94% | -82.18% | -75.94% | -69.36% |
| Operating Income | -39.08M | -77.45M | -56.74M | -43.01M | -48.16M | -37.23M | -28.87M | -22.22M |
| Operating Income Ratio | -56.91% | -115.94% | -50.08% | -34.21% | -100.12% | -87.86% | -81.11% | -73.78% |
| Total Other Income/Expenses | -18.99M | -12.86M | -2.71M | -8.49M | -3.04M | -5.24M | -2.44M | -849.00K |
| Income Before Tax | -58.07M | -113.25M | -59.88M | -51.50M | -51.21M | -42.47M | -31.01M | -23.07M |
| Income Before Tax Ratio | -84.56% | -169.53% | -52.85% | -40.96% | -106.45% | -100.21% | -87.10% | -76.60% |
| Income Tax Expense | 126.00K | 11.00K | -76.00K | 4.71M | -146.00K | 2.41M | 206.00K | 127.00K |
| Net Income | -58.19M | -113.26M | -59.80M | -56.21M | -51.06M | -42.47M | -31.01M | -23.07M |
| Net Income Ratio | -84.74% | -169.55% | -52.78% | -44.71% | -106.14% | -100.21% | -87.10% | -76.60% |
| EPS | -9.64 | -33.89 | -18.48 | -18.88 | -21.96 | -116.95 | -357.12 | -394.95 |
| EPS Diluted | -9.64 | -33.89 | -18.44 | -18.88 | -21.96 | -116.95 | -357.12 | -394.95 |
| Weighted Avg Shares Out | 6.04M | 3.34M | 3.24M | 2.98M | 2.33M | 363.14K | 86.82K | 58.42K |
| Weighted Avg Shares Out (Dil) | 6.04M | 3.34M | 3.24M | 2.98M | 2.33M | 363.14K | 86.82K | 58.42K |
Shareholder Alert: Ademi LLP investigates whether Vapotherm, Inc. has obtained a Fair Price for its Public Shareholders
Investors In VAPO Can Participate In Vapotherm Inc Investigation Conducted By Schall Law Firm
Doublepoint's WowMouse AR Enhances Users' Experience on Magic Leap 2, Debuts at AWE 2024 as First Wrist-Worn Gesture Control for Augmented Reality
VAPO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Vapotherm, Inc. Is Fair to Shareholders
Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private
Vapotherm Reports First Quarter 2024 Financial Results
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market
Source: https://incomestatements.info
Category: Stock Reports